Preclinical trial of Bacteriosens used for the photodynamic therapyof malignant tumors, including prostate cancer

Introduction.Bacteriochlorins are the most promising photosensitizers absorbing in the near-infrared spectral region. Their use can enhance the efficiency of photodynamic therapy due to the deeper penetration of radiation into the tumor.

Objective to conduct a preclinical study of the photoinduced antitumor activity and biodistribution of Bacteriosens.

Materials and methods.Bacteriosens is a preparation based on meso-tetra(3-pyridyl)bacteriochlorin absorbing at 747 nm. Photoinduced cytotoxicity was investigated in vitro using human tumor cells: A549, Hep 2, BT-474, MCF-7, SK-BR-3, PC3, and EJ and murine tumor cells: S37, C26, and LLC. In vivo studies were performed in mice with large and small tumors (S37, LLC, and C26).

Results.In vitro investigation show that bacteriosens during optical irradiation led to the effective suppression of tumor cell growth in culture (the IC50 value varied from 0,08μМ to 1,21 μМ) and had no toxicity without exposure to light. The effective photodynamic therapy regimen using Bacteriosens in mice with inoculated small and large tumors of different genesis resulted in regression of a primary tumor node on 90–100 % of the animals in the absence of tumor recurrence within 90 days after treatment.

Conclusion.Bacteriosens is a promising agent for the photodynamic therapy of small and large tumors; it can be successfully used as an alternative, organ-sparing minimally invasive treatment for malignant tumors, including prostate cancer.

1. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2018, 250 p. (In Russ.)

2. Moiseenko T.N., Govorov A.V., Prokopovich M.A., Pushkar D.Y. Modern aspects of the radical treatment of the prostate cancer using robotic surgery. Tuberkulez i sotsial’no znachimye zabolevaniya = Tuberculosis and socially significant diseases 2014;3:66–71 (In Russ.).

3. Martov A.G., Parkhonin D.I. Laparoscopic pelvic lymphadenectomy for located prostate cancer. Rossiysky Onkologichesky Zhurnal = Russian journal of oncology 2010;6:39–41 (In Russ.)

4. Khmelevsky E.V., Panshin G.A., Kancheli I.N., Khoroshkov V.S. Options of hypofractionation of proton boost in locally advanced prostate cancer. Voprosy onkologii = Problems in oncology 2012;58(6):787–94 (In Russ.)

5. Singh A., Cheedella N.K. S., Shakil S.A. et al. Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy. World J. Oncol. 2015;6(1);265–9. DOI: 10.14740/wjon903w. PMID: 29147414.

6. Fomkin R.N., Popkov V.M., Shatylko T.V. Alternative variant of the combined treatment of a localized cancer of a prostate. Byulleten’ meditsinskih Internet-konferentsiy = Bulletin of Medical Internet Conferences 2016;6(2):296–300 (In Russ.)

7. Al-Shukri S.Kh., Borovets S.Yu., Rybalov M.A., Saidov R.B. Current methods for local treatment of prostate cancer. Nephrology 2009;13(3):153–8 (In Russ.)

8. Fomkin R.N., Popkov V.M., Masljakova G.N. et al. Robotized highintensive focused ultrasonic ablation in treatment of a localized cancer of a prostate: 7 years of experience. Byulleten’ meditsinskih Internet-konferentsiy = Bulletin of Medical Internet Conferences 2017;7(2):529–34 (In Russ.)

9. Gheewala T., Skwor T., Munirathinam G. Photosensitizers in prostate cancer therapy. Oncotarget 2017;8(18):30524–38. DOI: 10.18632/oncotarget.15496. PMID: 8430624.

10. Kashchenko V.A., Raspereza D.V., Tvorogov D.A., Dobrun M.В. Photodynamic therapy: from fundamental research to Practice. The bulletin of the St. Petersburg university 2015;11(1):5–12 (In Russ.)

11. Zhu T.C., Kim M.M., Liang X. et al. Invivo singlet oxygen threshold doses for PDT. Photonics Lasers Med. 2015;4(1):59–71. DOI: 10.1515/plm-2014–0037. PMID: 25927018.

12. Agostinis P., Berg K., Cengel K.A. et. al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011;61(4): 250–81. DOI: 10.3322/caac.20114. PMID: 21617154.

13. Barrett T., Davidson S.R., Wilson B.C. et al. Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy. Can Urol Assoc J. 2014;8(9–10):708–14. DOI: 10.5489/cuaj.2176. PMID: 25408811.

14. Shafirstein G., Bellnier D., Oakley E. et al. Interstitial Photodynamic Therapy – A Focused Review. Cancers (Basel) 2017;9(2):E12. DOI: 10.3390/cancers9020012. PMID: 28125024.

15. Chilakamarthi U., Giribabu L. Photodynamic Therapy: Past, Present and Future. Chem. Rec. 2017;17(8): 775–802. DOI: 10.1002/tcr.201600121. PMID: 28042681.

16. Mironov A.F., Grin M.A. Bacteriochlorin sensitizers: prospects of use in photodynamic therapy. Vestnik MITHT = Bulletin of Moscow state University of Fine Chemical Technologies 2006;(4):5–28 (In Russ.)

17. Krzykawska-Serda M., Dąbrowski J.M., Arnaut L.G. et al. The role of strong hypoxia in tumors after treatment in the outcome of bacteriochlorinbased photodynamic therapy. Free Radic. Biol. Med. 2014;73:239–51. DOI: 10.1016/j.freeradbiomed. 2014.05.003. PMID: 24835769.

18. Patent RU № 2549953/10.05.2015, Bul. № 13. Makarova E.A., Jakubovskaja R.I., Vorozhtsov G.N., et al. Photosensitizers for photodynamic therapy(In Russ.) URL: http://www1.fips.ru/fips_servl/fips_servlet

19. American Type Culture Collection (ATCC) [Электронный ресурс]. URL: https://www.lgcstandards-atcc.org/?geo_country=ru

20. Institute of Cytology RAS – collection of cell cultures of vertebrates (In Russ.) URL: http://www.cytspb.rssi.ru/rkkk/rkkk_ru.htm.

21. Yakubovskaya R.I., Kazachkina N.I., Karmakova T.A. et al. Methodical recommendations on the study of photoinduced antitumor properties of drugs. In: Guide to conducting preclinical studies of medicines. Ed. by A.N. Mironov. Moscow: Grif i K, 2012:657–71 (In Russ.)